Ranbaxy facilities searched by FDA

Share this article:
Federal officials Wednesday conducted a search of the New Jersey offices and manufacturing facilities of Indian generic drugmaker Ranbaxy Laboratories. A company spokesman said in published reports that the action came as a surprise. “We’re not aware of any wrongdoing,” Ranbaxy spokesman Charles Caprariello said in a published report. “We’re cooperating and providing them with (material) even today.” Caprariello said officials from the FDA searched two Ranbaxy sites in New Jersey – a manufacturing plant in New Brunswick and administrative offices in Princeton. He declined to comment on whether the officials removed anything from the sites. “We’re working with the authorities to address the issues and hopefully resolve everything so we can get back to business as normal,” he said. Caprariello told The Wall Street Journal that the management team remains intact and employees are being informed about what has happened. Inquires to the FDA from news agencies about the searches were referred to the Justice Department. A Justice Department spokeswoman told the Associated Press, “We don’t comment on ongoing investigations.” Ranbaxy is based in Gurgaon, India and is that nation’s largest drug company. Last month, the company received approval to make a generic version of Pfizer’s blockbuster antidepressant Zoloft. Other generic drugmakers already had approval for generic versions.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...